Back to Search Start Over

Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management.

Authors :
van Diepen S
Pöss J
Senaratne JM
Gage A
Morrow DA
Source :
Circulation [Circulation] 2024 Oct 29; Vol. 150 (18), pp. 1459-1468. Date of Electronic Publication: 2024 Oct 28.
Publication Year :
2024

Abstract

The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as CS with at least 1 additional shock state . Mixed CS states are now the second leading cause of shock in contemporary coronary intensive care units, but there is little high-quality evidence to guide routine care, and there are no standardized classification frameworks or well-established hemodynamic definitions. This primer summarizes the current epidemiology and proposes a classification framework and invasive hemodynamic parameters to guide categorization that could be applied to help better phenotype patients captured in registries and trials, as well as guide management of mixed CS states.<br />Competing Interests: Dr Morrow is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Abiomed, Amgen, Anthos Therapeutics, Arca Biopharma, AstraZeneca, Daiichi‐Sankyo, Intarcia, Janssen, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Regeneron, Roche, Siemens, and Zora Biosciences. Dr Morrow has received consulting fees from Abbott Laboratories, Arca Biopharma, InCarda, Inflammatix, Merck, Novartis, and Roche Diagnostics. Dr Gage has received an educational honorarium from Zoll and is a former member of the Abiomed speaker’s bureau. Dr Pöss has received research funding (institutional) from the German Cardiac Society, Dr Rolf M. Schwiete Foundation, German Heart Research Foundation, and Maquet Cardiopulmonary GmbH. The other authors report no conflicts.

Details

Language :
English
ISSN :
1524-4539
Volume :
150
Issue :
18
Database :
MEDLINE
Journal :
Circulation
Publication Type :
Academic Journal
Accession number :
39466889
Full Text :
https://doi.org/10.1161/CIRCULATIONAHA.124.069508